$4.54
+0.06 (+1.34%)
Open$4.52
Previous Close$4.48
Day High$4.68
Day Low$4.44
52W High$29.98
52W Low$4.46
Volume—
Avg Volume70.2K
Market Cap44.93M
P/E Ratio—
EPS$-2.33
SectorBiotechnology
Analyst Ratings
Strong Buy
8 analysts
Price Target
+466.7% upside
Current
$4.54
$4.54
Target
$25.73
$25.73
$18.91
$25.73 avg
$33.51
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 880.9K | 3.10M | 47.44M |
| Net Income | 6.36M | 20.16M | 5.52M |
| Profit Margin | 721.9% | 685.8% | 11.6% |
| EBITDA | -10,213,194 | -34,187,929 | 8.75M |
| Free Cash Flow | — | — | 3.59M |
| Rev Growth | -71.6% | -71.6% | +12.6% |
| Debt/Equity | — | — | 0.48 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $249.46 | -0.54% | 70.2 | 443.23B |
| AMGN | Amgen Inc | $415.21 | -0.63% | 25.8 | 225.90B |
| GILD | Gilead Sciences Inc | $138.36 | +0.16% | — | 169.87B |
| VRTX | Vertex Pharmaceuticals Inc | $505.75 | -2.07% | 30.7 | 135.24B |
| REGN | Regeneron Pharmaceuticals | $803.48 | -0.31% | 19.0 | 82.16B |
| ALNY | Alnylam Pharmaceuticals Inc | $228.65 | +0.67% | 37.6 | 30.39B |